Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Taxotere docetaxel: Phase III data; marketed to treat locally advanced or metastatic breast cancer after failure of prior chemotherapy

In a 207-patient Phase III study, the one-year and 20-month survival rates of

Read the full 131 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE